← FDA DRUG APPROVALS

FDA ANDA · ANDA207426

SODIUM NITROPRUSSIDE

Sponsor: SAGENT PHARMS INC

APPLICATION
ANDA207426
TYPE
ANDA
ORIGINAL APPROVAL
2016-12-08
LATEST ACTION
2016-12-08
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

SODIUM NITROPRUSSIDEPrescription
SODIUM NITROPRUSSIDE 25MG/ML · INJECTABLE · INJECTION

Approval history

2016-12-08UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →